Application of VEGF (Vascular Endothelial Growth Factor) receptor fusion protein in preparation of medicament treating sepsis

A technology of fusion protein and therapeutic drug, applied in the field of VEGF inhibitor, which can solve problems such as sepsis

Active Publication Date: 2012-07-18
CHENGDU KANGHONG BIOTECH
View PDF6 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Antibiotics play an important role in the treatment of sepsis, but the problem that cannot be solved is that the infection of pathogenic microorganisms is only the initial trigger of sepsis. Although antibiotics can kill some pathogenic microorganisms, the large amount of endotoxin produced during

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of VEGF (Vascular Endothelial Growth Factor) receptor fusion protein in preparation of medicament treating sepsis
  • Application of VEGF (Vascular Endothelial Growth Factor) receptor fusion protein in preparation of medicament treating sepsis
  • Application of VEGF (Vascular Endothelial Growth Factor) receptor fusion protein in preparation of medicament treating sepsis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] Example 1 Fusion protein FP1, FP2, FP3, FP4, FP5, FP6, FP7, FP8 and VEGF binding affinity experiments

[0043] The present invention determines the ability of various fusion proteins to bind VEGF by measuring the amount of free VEGF. In this experiment, a certain amount of VEGF (10PM) was added to a centrifuge tube, and then fusion proteins FP1, FP2, FP3, FP4, FP5, FP6, FP7, and FP8 containing a certain concentration gradient were added to centrifuge tubes containing VEGF. tube, mix well and store in a 37°C incubator for one hour. One hour later, the free VEGF in each centrifuge tube was determined by the VEGF detection kit (VEGF assay Kit) provided by R&D systems (R&D systems). The Half Maximal Inhibitory Concentration (IC50) was used as the indicator of affinity, and the smaller the IC50, the stronger the affinity.

[0044]The fusion proteins FP1, FP2, FP3, FP4, FP5, FP6, FP7, and FP8 can all effectively bind to VEGF, and their IC50 values ​​are shown in the appendi...

Embodiment 2

[0045] Example 2 Effects of fusion proteins FP1, FP2, FP3, FP4, FP5, FP6, FP7, FP8 on the survival rate and plasma VEGF of LPS sepsis rats

[0046] In this experiment, a rat model of sepsis was established by intravenous injection of lipopolysaccharide (LPS) (refer to Schultz M J et al. (2002), Ann Med, 34:573-581). 270 clean-grade male rats, weighing 200g-240g, were each given intravenous injection of lipopolysaccharide (LPS) 30mg / kg, and were randomly divided into 9 groups, 30 in each group. One group is the control group, and the rest are the fusion protein FP1, FP2, FP3, FP4, FP5, FP6, FP7, FP8 treatment groups in turn. The control group received an intravenous injection of equal volume of normal saline, and the fusion protein treatment group received an intravenous injection of 10 mg / kg of the corresponding fusion protein. The number of surviving rats was recorded from 0 to 96 hours after completion.

[0047] Blood was drawn from the heart of the rats that died in the e...

Embodiment 3

[0050] Example 3 Effects of fusion proteins FP1 and FP3 on the level of TNF-α in CLP sepsis rats

[0051] Clean-grade male rats, weighing 230g-260g, were used to prepare rat models of cecal ligation and puncture (CLP) sepsis (refer to Chaudry IH et al. (1979), Surgery, 85: 205-211). 112 animals were randomized into groups. 1, 8 rats in the normal group; 2, 8 rats in the sham-operated group; 3, 32 rats in the control group: executed at 2 hours, 8 hours, 24 hours, and 48 hours after operation (each 8 rats); 4, FP1 administration group 32 rats: FP16mg / kg was administered intravenously after the operation, and they were killed at 2, 8, 24, and 48 hours respectively (8 each); , 24, 48 hours to kill (8 each). The experimental animals were killed alive after anesthesia, the abdominal aortic blood was collected, the serum was separated, and stored at -80°C after aliquoting; the liver and lungs were also taken and stored in liquid nitrogen.

[0052] Detection of TNF-α: Liver and lun...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to one or more VEGF (Vascular Endothelial Growth Factor) inhibitors which are selected from VEGF receptor fusion proteins including FP1, FP2, FP3, FP4, FP5, FP6, FP7 and FP8 and are used for treating inflammatory reaction accompanied by VEGF rising. The inflammatory reaction mainly comprises but is not limited to sepsis, severe sepsis and sepsis shock. The fusion proteins including FP1, FP2, FP3, FP4, FP5, FP6, FP7 and FP8 can be combined with one or more other medicaments and treatment means to treat the inflammatory reaction accompanied by the rising VEGF.

Description

[0001] This application is a divisional case of a Chinese invention patent application with an application date of October 13, 2008, an application number of 200810046277.2, and an invention titled "Application of VEGF receptor fusion protein in the preparation of drugs for the treatment of inflammation accompanied by elevated VEGF" Application. technical field [0002] The present invention relates to the use of one or more VEGF inhibitors selected from VEGF receptor fusion proteins FP1, FP2, FP3, FP4, FP5, FP6, FP7, and FP8 for the treatment of inflammatory response accompanied by VEGF elevation. Background technique [0003] Severe systemic inflammation in the body is called systemic inflammatory response syndrome (Systemic Inflammatory Response Syndrome, SIRS), and SIRS caused by clear pathogenic microorganisms (such as bacteria, viruses, fungi, parasites, etc.) is collectively called sepsis (Sepsis), and according to the severity of symptoms can be divided into sepsis (...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395A61K9/14A61K9/08A61P31/00A61P29/00
Inventor 俞德超王敬章
Owner CHENGDU KANGHONG BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap